ATE285785T1 - Hgf mutant und dessen verwendung als antikrebsmittel - Google Patents

Hgf mutant und dessen verwendung als antikrebsmittel

Info

Publication number
ATE285785T1
ATE285785T1 AT96935432T AT96935432T ATE285785T1 AT E285785 T1 ATE285785 T1 AT E285785T1 AT 96935432 T AT96935432 T AT 96935432T AT 96935432 T AT96935432 T AT 96935432T AT E285785 T1 ATE285785 T1 AT E285785T1
Authority
AT
Austria
Prior art keywords
alpha
hgf
fragment
active ingredient
anticancer agent
Prior art date
Application number
AT96935432T
Other languages
English (en)
Inventor
Toshikazu Nakamura
Original Assignee
Toshikazu Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshikazu Nakamura filed Critical Toshikazu Nakamura
Application granted granted Critical
Publication of ATE285785T1 publication Critical patent/ATE285785T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96935432T 1995-10-24 1996-10-23 Hgf mutant und dessen verwendung als antikrebsmittel ATE285785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30072895A JP3832674B2 (ja) 1995-10-24 1995-10-24 抗癌剤
PCT/JP1996/003105 WO1997016205A1 (fr) 1995-10-24 1996-10-23 Agent antitumoral

Publications (1)

Publication Number Publication Date
ATE285785T1 true ATE285785T1 (de) 2005-01-15

Family

ID=17888391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96935432T ATE285785T1 (de) 1995-10-24 1996-10-23 Hgf mutant und dessen verwendung als antikrebsmittel

Country Status (7)

Country Link
EP (1) EP0890361B1 (de)
JP (1) JP3832674B2 (de)
AT (1) ATE285785T1 (de)
CA (1) CA2235805C (de)
DE (1) DE69634138T2 (de)
ES (1) ES2235200T3 (de)
WO (1) WO1997016205A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU784359B2 (en) * 1999-12-15 2006-03-16 Entremed, Inc Compositions and methods for inhibiting endothelial cell proliferation
EP1320384B1 (de) 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2007110698A2 (en) * 2005-11-16 2007-10-04 Fariba Nayeri Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors
WO2009125831A1 (ja) * 2008-04-11 2009-10-15 有限会社スリーピー Ｎｋ４に対するモノクローナル抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
JP3030386B2 (ja) * 1991-05-15 2000-04-10 敏一 中村 抗ガン剤
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
ATE160585T1 (de) * 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie

Also Published As

Publication number Publication date
DE69634138D1 (de) 2005-02-03
EP0890361A4 (de) 2001-04-11
JPH09110716A (ja) 1997-04-28
ES2235200T3 (es) 2005-07-01
DE69634138T2 (de) 2006-02-09
WO1997016205A1 (fr) 1997-05-09
CA2235805C (en) 2008-10-28
EP0890361A1 (de) 1999-01-13
CA2235805A1 (en) 1997-05-09
EP0890361B1 (de) 2004-12-29
JP3832674B2 (ja) 2006-10-11

Similar Documents

Publication Publication Date Title
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
CZ143795A3 (en) 7-halo and 7-beta, 8-betamethanotaxols, their anti-neoplastic use and pharmaceutical compositions containing thereof
EP1015008A4 (de) Verbindungen und zusammensetzungen zur administration aktiver stoffe
TR200200717T2 (tr) Terapötik kinazolin türevleri.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
HU9302330D0 (en) 7-(substituted)-9-|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
ATE240951T1 (de) Benzopyran enthaltende verbindungen und deren prodrugformen
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
MY130544A (en) Antineoplastic use and pharmaceutical compositions containing them
ATE171170T1 (de) 7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
AU2001271987A1 (en) Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
AR005999A1 (es) Nuevos derivados de eritromicina, su procedimiento de preparacion, composiciones farmaceuticas y medicamentos
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
TR200003166T2 (tr) N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
RU2000131178A (ru) Метаболиты эктейнасцидина 743
DE60209721D1 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
MEP16208A (en) A combination comprising combretastatin and anticancer agents
DE69634138D1 (de) HGF Mutant und dessen Verwendung als Antikrebsmittel
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
IL137964A0 (en) Antitumor agents
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties